Get startedLog in
    Picture of Cidara Therapeutics logo

    CDTX — Cidara Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    Brief: Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial

    Picture of Cidara Therapeutics logoCidara Therapeutics
    23/06/2025 12:02
    June 23 (Reuters) - Cidara Therapeutics Inc CDTX.O:

CIDARA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B NAVIGATE TRIAL EVALUATING CD388, A NON-VACCINE PREVENTATIVE OF SEASONAL INFLUENZA

CIDARA THERAPEUTICS INC - STUDY MEETS PRIMARY AND SECONDARY EFFICACY ENDPOINTS

CIDARA THERAPEUTICS INC - CD388 DOSES SHOW 76%, 61%, AND 58% PROTECTION FROM INFLUENZA

CIDARA THERAPEUTICS INC - CD388 WELL-TOLERATED WITH NO SAFETY SIGNALS OBSERVED

Source text: ID:nGNX5vkFJz

Further company coverage: CDTX.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Cidara Therapeutics

    See all news